EQS-News

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio)

EQS-News: Formycon AG / Key word(s): Market Launch Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio) 11.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // April 11, 2024

 

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (Ranopto^TM) and Switzerland (Ranivisio)
 

• Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide
• Lucentis biosimilar FYB201 is an effective and cost-efficient treatment option for patients with serious retinal diseases
• Commercialization partner Teva markets FYB201 in Canada under the trademark Ranopto^TM and in Switzerland under the trademark Ranivisio
   

Munich, Germany – Formycon AG (FSE: FYB) and Bioeq AG announce the commercial launch of FYB201, a biosimilar to Lucentis¹(Ranibizumab), in Canada and Switzerland. The launch follows the marketing authorization granted by Health Canada under the trademark Ranopto^TM2and Swissmedic under the trademark Ranivisio³.

"Due to demographic developments, more and more people are affected by age-related macular degeneration and other retinal diseases, especially in industrialized nations. These diseases are often accompanied by a severe impairment in the quality of life. FYB201 is a new high-quality, effective and yet affordable treatment option for patients affected by such debilitating conditions. Teva is a strong commercialization partner with a proven track record in successfully launching FYB201 across major European markets and - like us - is convinced of the great potential of our biosimilar," commented Nicola Mikulcik, CBO of Formycon AG.

FYB201 was developed by Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV. As a biosimilar to Lucentis, FYB201 has already proven to be an important, cost-effective treatment option for patients with severe retinal diseases in the USA and large parts of Europe. In mid-2021, Bioeq and Teva entered into a strategic partnership for the exclusive commercialization of FYB201 in Canada, Europe and other territories. In Canada and Switzerland, FYB201 has been approved for the treatment of age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.